SDIC Securities released a research report on April 16 stating that it gave Innote (688253.SH) a purchase rating, and the target price was 42.13 yuan. The main reasons for the rating include: 1) Incident: Innote released its 2023 annual report for the first quarter of 2024, and the performance is in line with expectations; 2) actively lays out overseas business to build a second development engine; 3) demand+policy aspects drive the boom in the respiratory pathogen testing industry; 4) the risk that assumptions and predictions fall short of expectations, the risk that the market's demand for respiratory pathogen detection products falls short of expectations, and the risk of further intensification of industry competition. (Mainichi Keizai Shimbun)
国投证券4月16日发布研报称，给予英诺特（688253.SH）买入评级，目标价格为42.13元。评级理由主要包括：1）事件：英诺特发布2023年年报2024年一季度季报，业绩符合预期；2）积极布局海外业务，打造第二发展引擎；3）需求+政策两方面驱动呼吸道病原体检测行业高景气；4）假设及预测不及预期的风险、市场对呼吸道病原体检测产品的需求不及预期的风险、公司在研项目上市进程不及预期的风险、行业竞争进一步加剧的风险。（每日经济新闻）
SDIC Securities released a research report on April 16 stating that it gave Innote (688253.SH) a purchase rating, and the target price was 42.13 yuan. The main reasons for the rating include: 1) Incident: Innote released its 2023 annual report for the fir
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.